miércoles, 22 de mayo de 2019

Tocagen's brain cancer gene therapy trial continues. Investors worry

Tocagen's brain cancer gene therapy trial continues. Investors worry

Go West

STAT Plus: Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

By ADAM FEUERSTEIN


MICHELLE MONJE/STANFORD UNIVERSITY/NIH
Tocagen's Phase 3 clinical trial of a gene therapy for aggressive brain tumors will continue to a final analysis, a decision that will be debated.

No hay comentarios: